Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty

Core Viewpoint - Smith+Nephew has received 510(k) clearance from the FDA for its AETOS Stemless anatomic total shoulder system, marking a significant advancement in shoulder arthroplasty and addressing the growing demand for such procedures [1][2]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore people's bodies and self-belief through innovative technologies [5][6]. - The company generated annual sales of $5.5 billion in 2023 and operates in over 100 countries [6]. Product Details - The AETOS Stemless is designed to maximize metaphyseal fixation and stability, featuring an inlay collar, cruciate fins, and a porous titanium coating to encourage biological fixation [2]. - The AETOS Shoulder System, which includes the stemless implant, allows for streamlined convertibility from Stemless to Meta Stem, enhancing surgical flexibility [2]. Market Context - Total shoulder arthroplasty is one of the fastest-growing segments in orthopaedics, with an estimated 250,000 procedures expected annually in the US by 2025 [2]. - The AETOS Stemless expands Smith+Nephew's Upper Extremity portfolio, complementing its market-leading Sports Medicine shoulder repair and biologics solutions [2].